Verona Pharma plc Cash Flow Conversion Efficiency
Verona Pharma plc cash flow conversion efficiency. Based on the latest financial reports, Verona Pharma plc (I9SA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€30.56 Million ≈ $35.73 Million USD) by net assets (€278.27 Million ≈ $325.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Verona Pharma plc (2016–2024)
Cash flow conversion efficiency of Verona Pharma plc from 2016 to 2024. This chart illustrates how Verona Pharma plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View I9SA share price today for real-time trading data and today's change.
Verona Pharma plc Cash Flow Conversion Ratio Explained
Verona Pharma plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Verona Pharma plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma plc ranked by their cash flow conversion efficiency. Also see I9SA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hecla Mining Company
NYSE:HL
|
0.065x |
|
Subsea 7 S.A
F:SOCA
|
0.130x |
|
Brinker International Inc
NYSE:EAT
|
0.572x |
|
Indra A
MC:IDR
|
0.004x |
|
The Federal Bank Limited
NSE:FEDERALBNK
|
-0.058x |
|
FREEDOM HLDG DL-001
F:DMW2
|
-0.223x |
|
Nova Ltd
TA:NVMI
|
0.050x |
|
Max Healthcare Institute Limited
NSE:MAXHEALTH
|
0.076x |
Annual Cash Flow Conversion Efficiency for Verona Pharma plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma plc from 2016 to 2024. Review I9SA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €204.56 Million ≈ $239.15 Million |
€-122.20 Million ≈ $-142.87 Million |
-0.597x | -196.53% |
| 2023-12-31 | €249.28 Million ≈ $291.44 Million |
€-50.22 Million ≈ $-58.71 Million |
-0.201x | +22.44% |
| 2022-12-31 | €230.47 Million ≈ $269.44 Million |
€-59.86 Million ≈ $-69.98 Million |
-0.260x | -15.61% |
| 2021-12-31 | €148.00 Million ≈ $173.03 Million |
€-33.25 Million ≈ $-38.88 Million |
-0.225x | +7.86% |
| 2020-12-31 | €184.85 Million ≈ $216.11 Million |
€-45.08 Million ≈ $-52.70 Million |
-0.244x | +74.74% |
| 2019-12-31 | €44.40 Million ≈ $51.91 Million |
€-42.87 Million ≈ $-50.12 Million |
-0.965x | -325.69% |
| 2018-12-31 | €79.86 Million ≈ $93.36 Million |
€-18.11 Million ≈ $-21.17 Million |
-0.227x | -18.30% |
| 2017-12-31 | €107.95 Million ≈ $126.21 Million |
€-20.70 Million ≈ $-24.20 Million |
-0.192x | -45.96% |
| 2016-12-31 | €42.53 Million ≈ $49.72 Million |
€-5.59 Million ≈ $-6.53 Million |
-0.131x | -- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more